Skip to content
OpenCapital
Get started

Emerald Holding EEX Exchange Offer (Note 12)

Exchange Offer (Note 12) at other companies

Centerspace logo
CenterspaceCSR
$43K-93.9%
Empire State Realty Trust logo
Empire State Realty TrustESRT
$5.99M+278%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$28.57M—
Macerich logo
MacerichMAC
$5.23M+4,335%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$52.83M—
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc. MPLT
$126.92M—

Other financials

Income statement

See full
Revenue$155.4M+5.2%
Operating income$19.5M-45.5%
Net income$7.2M-52.9%
EPS (diluted)$0.04-50.0%

Balance sheet

See full
Cash & equivalents$121.1M-56.3%
Total debt$502.6M-1.7%
Total equity$338.4M-13.7%
Total assets$1.2B+5.1%

Cash flow

See full
Operating cash flow$28.7M+128%
CapEx$200.0K0.0%
Free cash flow$28.5M+130%

Valuation

See full
Market cap$995.53M+3.2%
Enterprise value$1.38B+14.8%
P/S2.1×-0.2×

Profitability

See full
Gross margin63.5%—
Operating margin13.5%+1.8pp
Net margin-8.2%-9.8pp
FCF margin12.2%-0.1pp

Returns & leverage

See full
Return on equity-10.6%—
Debt / equity1.5×+0.2×
Current ratio0.9×-0.7×

Where this comes from

Reported directly by Emerald Holding in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.

The official record: Emerald Holding’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emerald Holding's exchange offer (note 12).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emerald Holding's exchange offer (note 12)?
Emerald Holding (EEX) reported exchange offer (note 12) of $0 in Q4 2025.
How has Emerald Holding's exchange offer (note 12) changed year-over-year?
Emerald Holding's exchange offer (note 12) decreased by 100.0% year-over-year, from $125.3M to $0.
What does exchange offer (note 12) mean?
Represents the total value of debt or other financial instruments converted into common equity during the reporting period. This metric highlights non-cash capital restructuring activities that impact the company's share count and leverage profile. Investors use this to assess potential dilution and the company's efforts to reduce debt obligations through equity issuance.